Matches in SemOpenAlex for { <https://semopenalex.org/work/W3019421123> ?p ?o ?g. }
Showing items 1 to 73 of
73
with 100 items per page.
- W3019421123 abstract "Abstract Background Psoriasis (PSO) is an inflammatory skin condition, impacting physical and psychological well-being. PSO patients may develop psoriatic arthritis (PsA), a painful joint disease that further impacts quality of life. The objective was to examine rates of metabolic disease and depression in patients with PSO and PsA. Methods Claims data linked to electronic medical records were examined (Jan-2007-Mar-2018). Prevalent PSO patients were followed until end of data collection and categorized based on development of PsA (PSO+PsA cohort; defined by ICD9/10 codes in patients without PsA at baseline). Follow-up rates of comorbidities, including metabolic disease and depression, were compared for those with/without PsA, presented as cases per 1,000 patient-years (1000PY). Results Progression to PsA occurred in 2,311 (12%) patients. Follow-up rates of hyperlipidemia, hypertension, diabetes, and cardiovascular disease in the PSO+PsA cohort were 1.4-times (326 vs 234/1000PY), 1.6-times (357 vs 228/1000PY), 1.7-times (119 vs 72/1000PY), and 1.4-times (71 vs 50/1000PY) that observed in the PSO-only cohort, respectively. In patients without baseline metabolic disease, higher rates in PSO+PsA vs PSO-only remained (approximately 1.5-times and 1.3-times higher rates of hypertension and hyperlipidemia, respectively). The rate of depression was 140 vs 92/1000PY in the PSO+PsA vs PSO-only cohort; when examined in patients without baseline depression, rates were about half that observed in the overall population (72 vs 49/1000PY). Conclusion PSO+PsA patients had a substantial clinical burden, characterized by 40-70% higher rates of metabolic disease and depression than for patients who did not progress to PsA. Disclosures W. Tillett: Consultancies; AbbVie, Celgene, Janssen, Lilly, Novartis, Pfizer and UCB Pharma. Grants/research support; AbbVie, Celgene and Lilly. M. Skornicki: Other; Employee of Aetion. P. Prince: Other; Employee of Aetion. R. Suruki: Other; Employee of UCB Pharma. E. Lee: Other; Employee of UCB Pharma. A. Louder: Other; Employee of Aetion." @default.
- W3019421123 created "2020-05-01" @default.
- W3019421123 creator A5002460426 @default.
- W3019421123 creator A5010193939 @default.
- W3019421123 creator A5031652209 @default.
- W3019421123 creator A5034693159 @default.
- W3019421123 creator A5037993782 @default.
- W3019421123 creator A5068785796 @default.
- W3019421123 date "2020-04-01" @default.
- W3019421123 modified "2023-10-17" @default.
- W3019421123 title "P280 Clinical burden of concomitant joint disease in psoriasis: a US-linked claims and electronic medical records database analysis" @default.
- W3019421123 doi "https://doi.org/10.1093/rheumatology/keaa111.273" @default.
- W3019421123 hasPublicationYear "2020" @default.
- W3019421123 type Work @default.
- W3019421123 sameAs 3019421123 @default.
- W3019421123 citedByCount "0" @default.
- W3019421123 crossrefType "journal-article" @default.
- W3019421123 hasAuthorship W3019421123A5002460426 @default.
- W3019421123 hasAuthorship W3019421123A5010193939 @default.
- W3019421123 hasAuthorship W3019421123A5031652209 @default.
- W3019421123 hasAuthorship W3019421123A5034693159 @default.
- W3019421123 hasAuthorship W3019421123A5037993782 @default.
- W3019421123 hasAuthorship W3019421123A5068785796 @default.
- W3019421123 hasBestOaLocation W30194211231 @default.
- W3019421123 hasConcept C126322002 @default.
- W3019421123 hasConcept C134018914 @default.
- W3019421123 hasConcept C139719470 @default.
- W3019421123 hasConcept C162324750 @default.
- W3019421123 hasConcept C195910791 @default.
- W3019421123 hasConcept C203014093 @default.
- W3019421123 hasConcept C2776260265 @default.
- W3019421123 hasConcept C2776867660 @default.
- W3019421123 hasConcept C2779134260 @default.
- W3019421123 hasConcept C2779384505 @default.
- W3019421123 hasConcept C2780564577 @default.
- W3019421123 hasConcept C2908647359 @default.
- W3019421123 hasConcept C555293320 @default.
- W3019421123 hasConcept C71924100 @default.
- W3019421123 hasConcept C72563966 @default.
- W3019421123 hasConcept C99454951 @default.
- W3019421123 hasConceptScore W3019421123C126322002 @default.
- W3019421123 hasConceptScore W3019421123C134018914 @default.
- W3019421123 hasConceptScore W3019421123C139719470 @default.
- W3019421123 hasConceptScore W3019421123C162324750 @default.
- W3019421123 hasConceptScore W3019421123C195910791 @default.
- W3019421123 hasConceptScore W3019421123C203014093 @default.
- W3019421123 hasConceptScore W3019421123C2776260265 @default.
- W3019421123 hasConceptScore W3019421123C2776867660 @default.
- W3019421123 hasConceptScore W3019421123C2779134260 @default.
- W3019421123 hasConceptScore W3019421123C2779384505 @default.
- W3019421123 hasConceptScore W3019421123C2780564577 @default.
- W3019421123 hasConceptScore W3019421123C2908647359 @default.
- W3019421123 hasConceptScore W3019421123C555293320 @default.
- W3019421123 hasConceptScore W3019421123C71924100 @default.
- W3019421123 hasConceptScore W3019421123C72563966 @default.
- W3019421123 hasConceptScore W3019421123C99454951 @default.
- W3019421123 hasLocation W30194211231 @default.
- W3019421123 hasOpenAccess W3019421123 @default.
- W3019421123 hasPrimaryLocation W30194211231 @default.
- W3019421123 hasRelatedWork W122273 @default.
- W3019421123 hasRelatedWork W1590677 @default.
- W3019421123 hasRelatedWork W1836420 @default.
- W3019421123 hasRelatedWork W3003365 @default.
- W3019421123 hasRelatedWork W3660307 @default.
- W3019421123 hasRelatedWork W5315387 @default.
- W3019421123 hasRelatedWork W630527 @default.
- W3019421123 hasRelatedWork W6525474 @default.
- W3019421123 hasRelatedWork W7481763 @default.
- W3019421123 hasRelatedWork W14769339 @default.
- W3019421123 isParatext "false" @default.
- W3019421123 isRetracted "false" @default.
- W3019421123 magId "3019421123" @default.
- W3019421123 workType "article" @default.